Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 913-918

  Yanagihara, Kazuhiro ^a,b   Yoshimura, Kenichi ^a   Niimi, Miyuki ^a   Yasuda, Hiroyasu ^a   Sasaki, Takahiko ^a   Nishimura, Takafumi ^a,b   Ishiguro, Hiroshi ^a,b   Matsumoto, Shigemi ^a,b   Kitano, Toshiyuki ^a,b   Kanai, Masashi ^a   Misawa, Akiko ^a   Tada, Harue ^a   Teramukai, Satoshi ^a   Mio, Tadashi ^b   Fukushima, Masanori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Docetaxel; Non small cell lung cancer; Phase II study; S 1; Second line chemotherapy; Third line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL; GEFITINIB; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERCREATINEMIA; HYPERPIGMENTATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; METABOLIC DISORDER; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; OXONIC ACID; SURVIVAL RATE; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 77956228013     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1239-7     Document Type: Article

References (29)

1. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database, National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch. http://www.seer.cancer.gov/ Accessed 3 March 2009
2. FA Shepherd J Dancey R Ramlau, et al. 2000 A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103 1:CAS:528:DC%2BD3cXktVyjsLc%3D 10811675
3. FV Fossella R DeVore RN Kerr, et al. 2000 Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens J Clin Oncol 18 2354 2362 1:CAS:528:DC%2BD3cXkvFWrsLg%3D 10856094
4. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009 1:CAS:528:DyaK3sXmtFKqsrk%3D 7689420
5. K Furuse M Kawahara K Hasegawa, et al. 2001 Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer Int J Clin Oncol 6 236 241 10.1007/PL00012111 1:CAS:528:DC%2BD3MXovVGhtrw%3D 11723745
6. K Kubota M Kawahara M Ogawara, et al. 2008 Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study Lancet Oncol 9 1135 1142 10.1016/S1470-2045(08)70261-4 1:CAS:528: DC%2BD1cXhsVWrsL7I 19013107
7. R Maruyama Y Nishiwaki T Tamura, et al. 2008 Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 4244 4252 10.1200/JCO.2007.15.0185 1:CAS:528:DC%2BD1cXhtF2it7bK 18779611
8. Y Wada K Yoshida T Suzuki, et al. 2006 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines Int J Cancer 119 783 791 10.1002/ijc.21879 1:CAS:528:DC%2BD28XntVeqtrY%3D 16557585
9. I Takahashi Y Emi Y Kakeji, et al. 2005 Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts Oncology 68 130 137 10.1159/000086767 1:CAS:528:DC%2BD2MXntFSntLc%3D 16006750
10. A Suto T Kubota M Fukushima, et al. 2006 Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice Oncol Rep 15 1517 1522 1:CAS:528:DC%2BD28XlvVOis7k%3D 16685389
11. K Yamaguchi T Shimamura I Hyodo, et al. 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 1803 1808 10.1038/sj.bjc.6603196 1:CAS:528:DC%2BD28XlsFequ7Y%3D 16773074
12. C Gridelli A Ardizzoni F Ciardiello, et al. 2008 Second-line treatment of advanced non-small cell lung cancer [state of the art: concise review] J Thorac Oncol 3 430 440 10.1097/JTO.0b013e318168c815 18379366
13. F Nelli G Naso A De Pasquale Ceratti, et al. 2004 Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial J Chemother 16 392 399 1:CAS:528: DC%2BD2cXntlWhtb0%3D 15332716
14. D Pectasides HP Kalofonos E Samantas, et al. 2001 An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy Anticancer Res 21 3005 3010 1:CAS:528:DC%2BD3MXovVWgt70%3D 11712802
15. CH Spiridonidis LR Laufman L Carman, et al. 2001 Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial Ann Oncol 12 89 94 10.1023/A:1008306616994 1:STN:280: DC%2BD3Mzit1OisQ%3D%3D 11249055
16. K Takeda S Negoro T Tamura, et al. 2009 Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104) Ann Oncol 20 835 841 10.1093/annonc/mdn705 1:STN:280:DC%2BD1MzgvVyntg%3D%3D 19164456
17. N Hanna FA Shepherd FV Fossella, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597 10.1200/JCO.2004.08.163 1:CAS:528:DC%2BD2cXpsVWmurk%3D 15117980
18. FA Shepherd J Rodrigues Pereira T Ciuleanu JD Hainsworth 2005 Erlotinib in previously treated non-small-cell lung cancer N Eng J Med 323 123 132 10.1056/NEJMoa050753
19. DR Spigel M Lin V O'Neill, et al. 2008 Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced non small cell lung cancer Cancer 112 2749 2755 10.1002/cncr.23490 1:CAS:528:DC%2BD1cXosVGgsrw%3D 18438878
20. K Kubota Y Nishiwaki T Tamura, et al. 2008 Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study J Thorac Oncol 3 1439 1445 10.1097/JTO.0b013e31818d6702 19057270
21. R Ramlau R Gervais M Krzakowski, et al. 2006 Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer J Clin Oncol 24 2800 2807 10.1200/JCO.2005.03.6491 1:CAS:528:DC%2BD28XntV2gsr8%3D 16682727
22. S Jones D Thompson J Barton, et al. 2008 A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer Clin Lung Cancer 9 154 159 10.3816/CLC.2008.n.023 1:CAS:528:DC%2BD1cXnvVCrtLg%3D 18621625
23. Y Takiguchi T Moriya Y Asaka-Amano, et al. 2007 Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer Lung Cancer 58 253 259 10.1016/j.lungcan.2007.06.004 17658654
24. YM Chen RP Perng CM Tsai J Whang-Peng 2006 A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy Lung Cancer 52 333 338 10.1016/j.lungcan.2006.01.015 16554106
25. S Atagi M Kawahara Y Kusunoki, et al. 2008 Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer J Thorac Oncol 3 1012 1017 10.1097/JTO.0b013e318183f8ed 18758304
26. JA Ajani J Faust K Ikeda, et al. 2005 Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma J Clin Oncol 23 6957 6965 10.1200/JCO.2005.01.917 1:CAS:528:DC%2BD2MXhtFCrsbjM 16145066
27. N Yamamoto T Tamura Y Kamiya, et al. 2000 Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol J Clin Oncol 18 2301 2308 1:CAS:528:DC%2BD3cXktlagsbk%3D 10829051
28. I Sekine N Yamamoto K Nishio N Saijo 2008 Emerging ethnic differences in lung cancer therapy Br J Cancer 99 1757 1762 10.1038/sj.bjc.6604721 1:CAS:528:DC%2BD1cXhsVajtbvK 18985035
29. SR Park MS Park YL Park, et al. 2007 CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients with metastatic gastric carcinoma treated with S-1 plus docetaxel. 2007 ASCO Annual Meeting Proceedings J Clin Oncol 25 230s (abstr 4633)